Banner Image
Mobile banner image

Pfizer Oncology
Development

Overview - by Phase

Geo Regions

View studies/programs by

Cancer Type Phase
Cancer types
Phases
Study status

Phase 1

Presentation Bispecific Gamma Delta-T-Cell Engager Directed to EGFR

Bispecific Gamma Delta-T-Cell Engager Directed to EGFR

PF-08046052, SGN-EGFRd2
Phase 1
Go to page Bispecific Gamma Delta-T-Cell Engager Directed to EGFR
Presentation BRAFi Next Generation

BRAFi Next Generation

PF-07799933, ARRY-440
Phase 1
Go to page BRAFi Next Generation
rotating image for CD228-directed Antibody-Anticalin® Bispecific Protein

CD228-directed Antibody-Anticalin® Bispecific Protein

PF-08046049, SGN-BB228 
Phase 1
Go to page CD228-directed Antibody-Anticalin® Bispecific Protein
rotating gif of SGN-35T

CD30-directed Antibody-Tripeptide MMAE Conjugate

PF-08046045, SGN-35T
Phase 1
Go to page CD30-directed Antibody-Tripeptide MMAE Conjugate
Presentation CDK2 Inhibitor

CDK2 Inhibitor

PF-07104091
Phase 1
Go to page CDK2 Inhibitor
Presentation CDK2 Inhibitor + CDK4 Inhibitor

CDK2 Inhibitor + CDK4 Inhibitor

PF-07104091
PF-07220060
Phase 1
Go to page CDK2 Inhibitor + CDK4 Inhibitor
image representing CDK4 Inhibitor

CDK4 Inhibitor

PF-07220060
Phase 1
Go to page CDK4 Inhibitor
Presentation KAT6 Inhibitor + CDK4 Inhibitor

KAT6 Inhibitor + CDK4 Inhibitor

PF-07248144
PF-07220060
Phase 1
Go to page KAT6 Inhibitor + CDK4 Inhibitor
Presentation Vepdegestrant (ARV-471)* + CDK4 Inhibitor

Vepdegestrant (ARV-471)* + CDK4 Inhibitor

PROTAC® Estrogen Receptor Degrader
PF-07220060
Phase 1
Go to page Vepdegestrant (ARV-471)* + CDK4 Inhibitor
Presentation CEACAM5-directed Antibody Drug Conjugate

CEACAM5-directed Antibody Drug Conjugate

PF-08046050, SGN-CEACAM5C
Phase 1
Go to page CEACAM5-directed Antibody Drug Conjugate
rotating image for Disitamab vedotin

Disitamab vedotin

HER2-directed Antibody Drug Conjugate
Phase 1
Go to page Disitamab vedotin
image representing elranatamab

Elranatamab

BCMA-CD3 Bispecific Antibody
Phase 1
Go to page Elranatamab
rotating image for Enfortumab vedotin

Enfortumab vedotin

Nectin-4-directed Antibody Drug Conjugate
Phase 1
Go to page Enfortumab vedotin
Presentation Mevrometostat (EZH2 Inhibitor) + Enzalutamide

Mevrometostat (EZH2 Inhibitor) + Enzalutamide

PF-06821497
Androgen Receptor Inhibitor
Phase 1
Go to page Mevrometostat (EZH2 Inhibitor) + Enzalutamide
orange rotating molecule

Felmetatug vedotin (B7-H4-directed Antibody Drug Conjugate)

PF-08046048, SGN-B7H4V
Phase 1
Go to page Felmetatug vedotin (B7-H4-directed Antibody Drug Conjugate)
Presentation Integrin alpha-V/beta-8 Antagonist

Integrin alpha-V/beta-8 Antagonist

PF-06940434 
Phase 1
Go to page Integrin alpha-V/beta-8 Antagonist
Presentation KAT6 Inhibitor

KAT6 Inhibitor

PF-07248144
Phase 1
Go to page KAT6 Inhibitor
image representing maplirpacept

Maplirpacept

SIRPα-IgG4 Fusion Protein

TTI-622/PF-07901801
Phase 1
Go to page Maplirpacept
Presentation MEK Brain Penetrant Inhibitor

MEK Brain Penetrant Inhibitor

PF-07799544, ARRY-134
Phase 1
Go to page MEK Brain Penetrant Inhibitor
Presentation Mevrometostat

Mevrometostat

EZH2 Inhibitor

PF-06821497
Phase 1
Go to page Mevrometostat
rotating gif for Non-Fucosylated CD70-directed Antibody

Non-Fucosylated CD70-directed Antibody

PF-08046040, SEA-CD70
Phase 1
Go to page Non-Fucosylated CD70-directed Antibody
Image representing palbociclib

Palbociclib

CDK 4/6 Inhibitor
Phase 1
Go to page Palbociclib
rotating gif of PF-08046054, SGN-PDL1V

PD-L1-directed Antibody Drug Conjugate

PF-08046054, SGN-PDL1V
Phase 1
Go to page PD-L1-directed Antibody Drug Conjugate
Presentation Sasanlimab

Sasanlimab

Anti-PD-1
Phase 1
Go to page Sasanlimab
green molecule rotates

Sigvotatug vedotin

Integrin beta-6 directed Antibody Drug Conjugate
Phase 1
Go to page Sigvotatug vedotin
Presentation STING Agonist

STING Agonist

PF-07820435
Phase 1
Go to page STING Agonist
rotating image of Tisotumab vedotin

Tisotumab vedotin

TF-directed Antibody Drug Conjugate
Phase 1
Go to page Tisotumab vedotin
rotating image of Tucatinib

Tucatinib

HER2 Tyrosine Kinase inhibitor
Phase 1
Go to page Tucatinib
Presentation Vepdegestrant (ARV-471)*

Vepdegestrant (ARV-471)*

PROTAC® Estrogen Receptor Degrader
Phase 1
Go to page Vepdegestrant (ARV-471)*

Phase 2

Presentation Encorafenib + Binimetinib

Encorafenib + Binimetinib

BRAF Inhibitor
MEK Inhibitor
Phase 2
Go to page Encorafenib + Binimetinib
rotating image for Brentuximab vedotin

Brentuximab vedotin

CD30-directed Antibody Drug Conjugate
Phase 2
Go to page Brentuximab vedotin
Presentation CDK2 Inhibitor

CDK2 Inhibitor

PF-07104091
Phase 2
Go to page CDK2 Inhibitor
Presentation CDK2 Inhibitor + CDK4 Inhibitor

CDK2 Inhibitor + CDK4 Inhibitor

PF-07104091
PF-07220060
Phase 2
Go to page CDK2 Inhibitor + CDK4 Inhibitor
image representing CDK4 Inhibitor

CDK4 Inhibitor

PF-07220060
Phase 2
Go to page CDK4 Inhibitor
Presentation Vepdegestrant (ARV-471)* + CDK4 Inhibitor

Vepdegestrant (ARV-471)* + CDK4 Inhibitor

PROTAC® Estrogen Receptor Degrader
PF-07220060
Phase 2
Go to page Vepdegestrant (ARV-471)* + CDK4 Inhibitor
rotating image for Disitamab vedotin

Disitamab vedotin

HER2-directed Antibody Drug Conjugate
Phase 2
Go to page Disitamab vedotin
image representing elranatamab

Elranatamab

BCMA-CD3 Bispecific Antibody
Phase 2
Go to page Elranatamab
Presentation Encorafenib

Encorafenib

BRAF Inhibitor
Phase 2
Go to page Encorafenib
rotating image for Enfortumab vedotin

Enfortumab vedotin

Nectin-4-directed Antibody Drug Conjugate
Phase 2
Go to page Enfortumab vedotin
image representing maplirpacept

Maplirpacept

SIRPα-IgG4 Fusion Protein

TTI-622/PF-07901801
Phase 2
Go to page Maplirpacept
Image representing palbociclib

Palbociclib

CDK 4/6 Inhibitor
Phase 2
Go to page Palbociclib
Presentation Sasanlimab

Sasanlimab

Anti-PD-1
Phase 2
Go to page Sasanlimab
rotating image of Tisotumab vedotin

Tisotumab vedotin

TF-directed Antibody Drug Conjugate
Phase 2
Go to page Tisotumab vedotin
rotating image of Tucatinib

Tucatinib

HER2 Tyrosine Kinase inhibitor
Phase 2
Go to page Tucatinib
Presentation Vepdegestrant (ARV-471)*

Vepdegestrant (ARV-471)*

PROTAC® Estrogen Receptor Degrader
Phase 2
Go to page Vepdegestrant (ARV-471)*

Phase 3

Presentation Encorafenib + Binimetinib

Encorafenib + Binimetinib

BRAF Inhibitor
MEK Inhibitor
Phase 3
Go to page Encorafenib + Binimetinib
rotating image for Brentuximab vedotin

Brentuximab vedotin

CD30-directed Antibody Drug Conjugate
Phase 3
Go to page Brentuximab vedotin
image representing CDK4 Inhibitor

CDK4 Inhibitor

PF-07220060
Phase 3
Go to page CDK4 Inhibitor
rotating image for Disitamab vedotin

Disitamab vedotin

HER2-directed Antibody Drug Conjugate
Phase 3
Go to page Disitamab vedotin
image representing elranatamab

Elranatamab

BCMA-CD3 Bispecific Antibody
Phase 3
Go to page Elranatamab
Presentation Encorafenib

Encorafenib

BRAF Inhibitor
Phase 3
Go to page Encorafenib
rotating image for Enfortumab vedotin

Enfortumab vedotin

Nectin-4-directed Antibody Drug Conjugate
Phase 3
Go to page Enfortumab vedotin
Presentation Vepdegestrant (ARV-471)* + Palbociclib

Vepdegestrant (ARV-471)* + Palbociclib

PROTAC® Estrogen Receptor Degrader
CDK 4/6 Inhibitor
Phase 3
Go to page Vepdegestrant (ARV-471)* + Palbociclib
Image representing palbociclib

Palbociclib

CDK 4/6 Inhibitor
Phase 3
Go to page Palbociclib
Presentation Sasanlimab

Sasanlimab

Anti-PD-1
Phase 3
Go to page Sasanlimab
green molecule rotates

Sigvotatug vedotin

Integrin beta-6 directed Antibody Drug Conjugate
Phase 3
Go to page Sigvotatug vedotin
Presentation Talazoparib

Talazoparib

PARP Inhibitor
Phase 3
Go to page Talazoparib
rotating image of Tisotumab vedotin

Tisotumab vedotin

TF-directed Antibody Drug Conjugate
Phase 3
Go to page Tisotumab vedotin
rotating image of Tucatinib

Tucatinib

HER2 Tyrosine Kinase inhibitor
Phase 3
Go to page Tucatinib
Presentation Vepdegestrant (ARV-471)*

Vepdegestrant (ARV-471)*

PROTAC® Estrogen Receptor Degrader
Phase 3
Go to page Vepdegestrant (ARV-471)*

Efficacy and safety of these products, for the uses identified within, are currently under investigation. Regulatory approval of any of these products or uses is dependent on the completion of the study programs and review by regulatory authorities. The clinical trial information is available at www.clinicaltrials.gov. This information is current as of January 30, 2024.

*Vepdegestrant is being co-developed with Arvinas Estrogen Receptor, Inc.

Anticalin® is a registered US trademark of Pieris Pharmaceuticals Gmbh.